Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Single-Arm Study of Crovalimab in aHUS (Japan)
jRCT2031210061Phase 3Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label, single-arm trial of crovalimab in atypical hemolytic uremic syndrome (aHUS), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Percentage of participants with complete TMA response. Started May 2022; status: active, not recruiting.
02
Drugs
crovalimab
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on jRCT2031210061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210061.